UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.12451Principal InvestigatorFidelman, Nicholas
PhaseIII (Cancer Control)
Age GroupAdultScopeNational
Secondary Protocol No.TS-102
TitleA Phase III Trial Evaluating TheraSphere in Patients with mCRC of the Liver who have Failed First Line Chemotherapy
ObjectiveTo evaluate the efficacy and safety of TheraSphere in patients with metastatic colorectal cancer of the liver scheduled to receive second line standard of care chemotherapy
Key EligibilityAge: 18+ * Colorectal cancer with metastases progressed after first line treatment
Applicable Disease SitesColon
Rectum
Therapies InvolvedRadiotherapy
StatusOpen
Participating InstitutionsMt. Zion : Ryan Mcwhirter
Parnassus : Ryan Mcwhirter
Eligibility Document12451_CTGovEligibility_NCT01483027.doc
Other AttachmentsCelGene website summary.apv PDF.pdf
ContactRyan Mcwhirter Phone:415-353-7792
Pager:
Email:McWhirterR@cc.ucsf.edu